GEN Exclusives

More »

GEN News Highlights

More »
May 8, 2008

Novartis Raises Ownership in Alnylam with $5.41M Procurement of Shares

  • Novartis has purchased additional shares of Alnylam Pharmaceuticals’ common stock for almost $5.41 million. The decision to fully exercise this right increases Novartis’ stake in Alnylam from 13% to 13.4%.

    As per the terms of a September 2005 investor rights agreement between the companies, Novartis decided to buy  213,888 unregistered shares of Alnylam’s common stock. The firm is paying $25.29 per share. Alnylam value at the end of yesterday was $24.84 and opened trading today at $25.51.

    Novartis previously purchased approximately 5.3 million shares at $11.11 per share, gaining a 13% ownership position. The company is permitted to own no more than 19.9% of Alnylam’s outstanding shares.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »